Piper Jaffray analyst Joshua Schimmer says that GW Pharmaceuticals is just "one more Phase 3 trial result away" from filing for approval of its Epidiolex for treatment of Dravet Syndrome and Lennox-Gastaut Syndrome refractory seizures, which should happen in the first half of 2017. Schimmer points out that while the company acknowledges that part of the Epidiolex treatment benefit may be coming from a favorable drug interaction, it notes that there is a "meaningful" clinical benefit regardless of background therapy. Schimmer reiterates an Overweight rating and $147 price target on the shares.